Literature DB >> 33496743

Chromosomal defects and survival in patients with adult T-cell leukemia/lymphoma after allogeneic HSCT.

Nobuaki Nakano1,2, Atae Utsunomiya1,2, Keitaro Matsuo3,4, Noriaki Yoshida5,6, Masao Seto5, Kouichi Ohshima5, Hiroshi Fujiwara7, Shigeo Fuji8, Yoshifusa Takatsuka1,2, Ayumu Ito9, Toshihiro Miyamoto10, Youko Suehiro11, Hirohisa Nakamae12, Yasushi Sawayama13, Mitsuhiro Yuasa14, Yasuhiko Miyazaki15, Shuichi Ota16, Kazunori Imada17, Takahiro Fukuda9, Tatsuo Ichinohe18, Yoshiko Atsuta19,20, Koji Kato10.   

Abstract

Adult T-cell leukemia/lymphoma (ATL) cells frequently exhibit chromosomal abnormalities, including numerical aberrations and structural defects. However, no studies have examined the correlation between these abnormalities and survival in patients with ATL after allogeneic HSCT (allo-HSCT). In this study, 300 patients with ATL (median age, 55 years; range, 24-74) who were registered in a Japanese nationwide registry database were analyzed. The majority (n = 183) had acute ATL. Specimens for chromosomal analysis were collected from bone marrow (n = 166), lymph nodes (n = 86), peripheral blood (n = 41), and other locations (n = 7). In survival analyses, breakpoints at 2q (hazard ratio [HR], 1.63; 95% confidence interval [CI], 1.12-2.38; P = .012) and 5q (HR, 2.18; 95% CI, 1.25-3.80; P = .006) were significantly poor prognostic factors for overall survival (OS). In terms of ATL-related death, loss of chromosome 14 and breakpoints at 3p, 1q, 5q, and 6q were extracted as significantly poor prognostic factors. Moreover, complex karyotypes were associated with ATL-related death. This study of the survival impact of chromosomal abnormalities in patients with ATL after allo-HSCT demonstrated that several structural breakpoints were independent risk factors for OS and ATL-related death.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2021        PMID: 33496743      PMCID: PMC7839361          DOI: 10.1182/bloodadvances.2020003639

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  21 in total

1.  Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy.

Authors:  Lee Ratner; Thomas A Waldmann; Murali Janakiram; Jonathan E Brammer
Journal:  N Engl J Med       Date:  2018-05-17       Impact factor: 91.245

2.  Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.

Authors:  Ali Bazarbachi; Yves Plumelle; Juan Carlos Ramos; Patricia Tortevoye; Zaher Otrock; Graham Taylor; Antoine Gessain; William Harrington; Gérard Panelatti; Olivier Hermine
Journal:  J Clin Oncol       Date:  2010-06-28       Impact factor: 44.544

3.  Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report.

Authors:  N Kamada; M Sakurai; K Miyamoto; I Sanada; N Sadamori; S Fukuhara; S Abe; Y Shiraishi; T Abe; Y Kaneko
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

4.  Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.

Authors:  Takashi Ishida; Hiroshi Fujiwara; Kisato Nosaka; Naoya Taira; Yasunobu Abe; Yoshitaka Imaizumi; Yukiyoshi Moriuchi; Tatsuro Jo; Kenichi Ishizawa; Kensei Tobinai; Kunihiro Tsukasaki; Shigeki Ito; Makoto Yoshimitsu; Maki Otsuka; Michinori Ogura; Shuichi Midorikawa; Wanda Ruiz; Tomoko Ohtsu
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

5.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

6.  Treatment of patients with adult T cell leukemia/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey.

Authors:  Koji Kato; Ilseung Choi; Atsushi Wake; Naokuni Uike; Shuichi Taniguchi; Yukiyoshi Moriuchi; Yasushi Miyazaki; Hirohisa Nakamae; Eijirou Oku; Makoto Murata; Tetsuya Eto; Koichi Akashi; Hisashi Sakamaki; Koji Kato; Ritsuro Suzuki; Takeharu Yamanaka; Atae Utsunomiya
Journal:  Biol Blood Marrow Transplant       Date:  2014-08-27       Impact factor: 5.742

7.  VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.

Authors:  Kunihiro Tsukasaki; Atae Utsunomiya; Haruhiko Fukuda; Taro Shibata; Takuya Fukushima; Yoshifusa Takatsuka; Shuichi Ikeda; Masato Masuda; Haruhisa Nagoshi; Ryuzo Ueda; Kazuo Tamura; Masayuki Sano; Saburo Momita; Kazunari Yamaguchi; Fumio Kawano; Shuichi Hanada; Kensei Tobinai; Masanori Shimoyama; Tomomitsu Hotta; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2007-10-29       Impact factor: 44.544

8.  Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Makoto Yoshimitsu; Ryuji Tanosaki; Koji Kato; Takashi Ishida; Ilseung Choi; Yoshifusa Takatsuka; Takahiro Fukuda; Tetsuya Eto; Michihiro Hidaka; Naoyuki Uchida; Toshihiro Miyamoto; Yasuhiro Nakashima; Yukiyoshi Moriuchi; Koji Nagafuji; Yasuhiko Miyazaki; Tatsuo Ichinohe; Minoko Takanashi; Yoshiko Atsuta; Atae Utsunomiya
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-16       Impact factor: 5.742

9.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.

Authors:  Jan Krönke; Emma C Fink; Paul W Hollenbach; Kyle J MacBeth; Slater N Hurst; Namrata D Udeshi; Philip P Chamberlain; D R Mani; Hon Wah Man; Anita K Gandhi; Tanya Svinkina; Rebekka K Schneider; Marie McConkey; Marcus Järås; Elizabeth Griffiths; Meir Wetzler; Lars Bullinger; Brian E Cathers; Steven A Carr; Rajesh Chopra; Benjamin L Ebert
Journal:  Nature       Date:  2015-07-01       Impact factor: 49.962

10.  Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation.

Authors:  Shigeo Fuji; Takuhiro Yamaguchi; Yoshitaka Inoue; Atae Utsunomiya; Yukiyoshi Moriuchi; Kaoru Uchimaru; Satsuki Owatari; Takashi Miyagi; Jun Taguchi; Ilseung Choi; Eiichi Otsuka; Sawako Nakachi; Hisashi Yamamoto; Saiko Kurosawa; Kensei Tobinai; Takahiro Fukuda
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

View more
  1 in total

1.  Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.

Authors:  Makoto Hirosawa; Midori Goto; Masahiko Oku; Kenichi Akao; Noriaki Kitamura; Tsukasa Nakanishi; Aya Tanaka; Daisuke Niino; Takehiro Higashi; Hiroaki Morimoto; Junichi Tsukada
Journal:  Int J Hematol       Date:  2022-09-09       Impact factor: 2.319

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.